Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q3 2018 · 10-Q
Revenue$40.79M$40.79M+50.1% vs Q3 2017 Net Income$5.24M$5.24MN/M vs Q3 2017 EPS Diluted$0.01$0.01— vs Q3 2017 Operating Income$7,018,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$9,255,000−22.1% Margins · derivedOperating margin17.2%+35.4 pt vs Q3 2017
Net margin12.9%+16.1 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 6, 2018 · 37 d after period end